Cue Biopharma: CUE-221 reached a major endpoint in clinical trials of chronic spontaneous urticaria.

Zhitongcaijing · 2d ago
Cue Biopharma: CUE-221 reached a major endpoint in clinical trials of chronic spontaneous urticaria.